AU676314B2 - Monohydrate dextrose or glucose composition - Google Patents
Monohydrate dextrose or glucose composition Download PDFInfo
- Publication number
- AU676314B2 AU676314B2 AU65844/94A AU6584494A AU676314B2 AU 676314 B2 AU676314 B2 AU 676314B2 AU 65844/94 A AU65844/94 A AU 65844/94A AU 6584494 A AU6584494 A AU 6584494A AU 676314 B2 AU676314 B2 AU 676314B2
- Authority
- AU
- Australia
- Prior art keywords
- document
- composition
- weight
- international
- documents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000203 mixture Substances 0.000 title claims description 25
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims description 19
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 title claims description 12
- 239000008121 dextrose Substances 0.000 title claims description 10
- 150000004682 monohydrates Chemical class 0.000 title claims description 10
- 239000008103 glucose Substances 0.000 title claims description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 16
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 6
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 6
- 235000019158 vitamin B6 Nutrition 0.000 claims description 6
- 239000011726 vitamin B6 Substances 0.000 claims description 6
- 229940011671 vitamin b6 Drugs 0.000 claims description 6
- 239000011787 zinc oxide Substances 0.000 claims description 6
- 235000010323 ascorbic acid Nutrition 0.000 claims description 5
- 239000011668 ascorbic acid Substances 0.000 claims description 5
- 229960005070 ascorbic acid Drugs 0.000 claims description 5
- 159000000003 magnesium salts Chemical class 0.000 claims description 4
- 231100000252 nontoxic Toxicity 0.000 claims description 4
- 230000003000 nontoxic effect Effects 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 3
- 239000000395 magnesium oxide Substances 0.000 claims description 3
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 3
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 3
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 3
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 3
- 235000011009 potassium phosphates Nutrition 0.000 claims description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims 3
- 102220547770 Inducible T-cell costimulator_A23L_mutation Human genes 0.000 claims 2
- 229930003231 vitamin Natural products 0.000 claims 2
- 229940088594 vitamin Drugs 0.000 claims 2
- 235000013343 vitamin Nutrition 0.000 claims 2
- 239000011782 vitamin Substances 0.000 claims 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000011777 magnesium Substances 0.000 description 7
- 229910052749 magnesium Inorganic materials 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 6
- 159000000001 potassium salts Chemical class 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 206010019133 Hangover Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000026473 slurred speech Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/60—Sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Description
PCT/z 9 4 0 0 4 2 RECEIVED 2 6 APR 1995 TITLE: MONOHYDRATE DEXTROSE OR GLUCOSE COMPOSITION Background of the Invention The present invention relates to a composition for the treatment of a "hangover" i.e. the after-effects of excessive consumption of ethyl alcohol by a human being.
Summary of the Invention An object of the invention is the provision of a composition which can be taken as a single treatment (in one or more doses) to counteract a hangover.
The present invention provides a composition including:a major proportion of monohydrate dextrose or glucose in combination with the following compounds: 0.5% 2% by weight ascorbic acid; 0.0001% 0.4% by weight of a non-toxic potassium salt; 0.0001% 0.4% by weight of a non-toxic magnesium salt; 0.001% 2.5% by weight vitamin B6; 0.0001% 0.07% by weight of zinc oxide.
Detailed Description of the Invention One of the known effects of alcohol in the human system is to lower the blood sugar, and this leads to an increase in Cf, AMENDED SHEET
IPEA/AU
WO 9;/27449 PCTINZ9400042 liver activity as the liver increases its normal rate of breaking down glycogen into blood sugar, to restore the optimum blood sugar level. Continual or frequent such increase in liver activity can lead to cirrhosis of the liver.
The brain uses about 25% of available blood sugar, and so is particularly rapidly effected by a drop in blood sugar levels:- hence the symptoms of slurred speech, memory lapses, headaches, loss of co-ordination, blurred vision, personality changes, and so on commonly associated with alcohol consumption.
Monohydrate dextrose breaks down to glucose in the body, and thus both monohydrate dextrose and glucose are quickly and readily assimilated into the blood stream to boost the blood sugar level and help prevent liver damage and counteract brain disfunction.
The presence of alcohol in the system also is believed to increase the amount and frequency of urine passed, leading to a depletion of vitamin C, (ascorbic acid), magnesium and potassium in the system, and these losses need to be replaced to allow the system to resume functioning correctly. Examples of suitable magnesium and potassium salts are magnesium sulphate, magnesium oxide, and potassium phosphate.
It is believed that the presence in the composition of only minute traces of magnesium and potassium salts will be sufficient to stimulate the release of adequate supplies of these salts from the body's own stores. An alternative explanation of the effectiveness of the compound of the WO 94/27449 PCT/NZ94/00042 present invention is that the body requires only minute traces of the magnesium and potassium salts to make up the deficiencies caused by alcohol. However, a higher proportion of magnesium and potassium salts may be advantageous. One or more potassium salts and one or more magnesium salts may be used.
Also, it is believed that the magnesium and potassium salts and vitamin C are much more readily and easily absorbed into the system if taken into the system with monohydrate dextrose or glucose:- the monohydrate' dextrose or glucose effectively coats said other constituents and prevents them from being destroyed by stomach acids, and also speeds their circulation around the system.
Zinc oxide assists the pancreas with the production of insulin, and hence facilitates the absorption of glucose into the blood. Zinc oxide also is known to be effective in detoxifying the system i.e. combatting the after-effects of alcohol.
It is believed that the presence of vitamin B6 in the composition considerably increases the rate of activity of the composition and thus gives more rapid relief to a user. It appears that vitamin B6 and magnesium salts are synergistic i.e. the presence of one increases the effectiveness of the other, and thus reduces the amount of each needed in the composition to achieve the desired effect.
Thus, the constituents of the composition act to raise the user's blood sugar level and replenish lost vitamin C, cl WO 94/27449 PCT/NZ94/00042 magnesium and potassium, and also interact with each other to mutually increase their effectiveness and to speed their assimilation into the system.
Optionally, the composition also may contain one or more of the following: 0.5% 2% by weight powdered citric acid, to improve the palatability of the coi;,position; 0.5% 5% by weight powdered calcium phosphate, to replenish calcium losses.
A preferred embodiment of the present composition comprises: 2.4% ascorbic acid; 1.1% citric acid; 0.4% vitamin B6; 0.1% magnesium sulphate; 0.1% potassium phosphate; 0.1% magnesium oxide; 0.03% zinc oxide; 95.77% monohydrate dextrose; (all by weight).
The composition is in the form of a powder, and is taken dissolved in water or in tablet form. It has been found that the composition is more effective if the user lies on the right side after taking the composition, because this allows the composition to pass more quickly though the duodenum into the intestine, for absorption into the system.
Alternatively, the composition may be prepared in liquid WO 94/27449 form, and drunk oi given by injection.
IICT/NZ94/00042
Claims (5)
1. A composition including:- a major proportion of monohydrate dextrose or glucose in combination with the following compounds: 0.5% 2% by weight ascorbic acid; 0.0001% 0.4% by weight of a non-toxic potassium salt; 0.0001% 0.4% by weight of a non-toxic magnesium salt; 0.001% 2.5% by weight vitamin B6; 0.0001% 0.07% by weight of zinc oxide.
2. The composition as claimed in Claim 1, further including 2% by weight of citric acid.
3. The composition as claimed in Claim 1 or Claim 2, further including 0.5% 5% by weight of calcium phosphate.
4. A composition comprising 2.4% ascorbic acid; 1.1% citric acid; 0.4% vitamin B6; 0.1% magnesium sulphate; 0.1% potassium phosphate; 0.1% magnesium oxide; 0.03% zinc oxide;
95.77% monohydrate dextrose; (all by weight). r, The composition as claimed in any preceding claim, 6 AMENDED SHEET IPEA/AU WO 94/27449 PCTINZ94/00042 wherein said composition is in the form of a powder. 6. The composition as claimed in any preceding claim, wherein said composition is in the form of a liquid. II I a INTERNATIONAL SEARCH REPORT International application No. PCT/NZ 94/00042 A. CLASSIFICATION OF SUBJECT MATTER Int. C1. 5 A23L 1/302, 1/304; A61K 31/375, 31/44, 31/70, 33/04, 33/08, 33/30, 33/42 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC A61K 31/375, 31/44, 31/70, 33/04, 33/08, 33/30, 33/42; A23L 1/302, 1/304 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched AU IPC as above Electronic data base consulted during the international search (name of data base, and where practicable, search terms used) DERWENT (VITAMIN( )B6 or PYRIDOX:( )HYDROCHLORIDE) AND (VITAMIN( )C OR ASCORBIC( )ACID) C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to Claim No. US,A, 5108767 (ABBOT LABORATORIES) 28 April 1992 (28.04.92) A See claims 1-19, on columns 15 and 16 1-6 US,A, 4710387 (MELKUNTE HOLLAND 1 December 1987 (01.12.87) A See claims 1-18 on columns 9 and 10 1-6 EP,A, 87068 (BECK) 31 August 1983 (31.08.83) A See whole document 1-6 Further documents are listed See patent family annex. in the continuation of Box C. S Special categories of cited documents later document published after the international filing date or priority date and not in conflict document definin the eneral state of the art which is with the appliation but cited to understand the not considered tobe of articular relevance principle or theory underlying the invention earlier document but published on or after the document of particular relevance; the claimed international filing date invention cannot be considered novel or cannot be document which may throw doubts on priority claim(s) considered to involve an inventive step when the or which is cited to establish the publication date of document is taken alone another citation or other special reason (as specified) document of particular relevance; the claimed document referring to an oral disclosure, use, invention cannot be considered to involve an exhibition or other means inventive step when the document is combined document published prior to the international filing date with one or more other such documents, such but later than the priority date claimed combination being obvious to a person skilled in the art document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 24 August 1994 (24.08.94) 3 1 AU 1994 3 1. 0 8,94 Name and mailing address of the ISA/AU AUSTRALIAN INDUSTRIAL PROPERTY ORGANISATION PO BOX 200 WODEN ACT 2606 AUSTRALIA Facsimile No. 06 2853929 At oz officer J. BODEGRAVEN Telephone No. (06) 2832281 Form PCT/ISA/210 (continuation of first sheet (July 1992) cophin I INTERNATIONAL SEARCH REPORT Information on patent family membe International application No, PCT/NZ 94/00042 This Annex lists the known publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information. Patent Document Cited in Search Patent Family Member Report US 5108767 AU 21542/92 CA 2099880 EP 587824 WO 9222218 US 4710387 EP 183305 NL 8403433 EP 87068 AU 11364/F3 JP 58/159408 ZA 8300906 END OF ANNEX Form PCT/ISA/210(patent family annex)(July 1992) cophin I
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ24770193 | 1993-05-26 | ||
| NZ247701 | 1993-05-26 | ||
| PCT/NZ1994/000042 WO1994027449A1 (en) | 1993-05-26 | 1994-05-10 | Monohydrate dextrose or glucose composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU6584494A AU6584494A (en) | 1994-12-20 |
| AU676314B2 true AU676314B2 (en) | 1997-03-06 |
Family
ID=19924357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU65844/94A Ceased AU676314B2 (en) | 1993-05-26 | 1994-05-10 | Monohydrate dextrose or glucose composition |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0700255A4 (en) |
| CN (1) | CN1124444A (en) |
| AU (1) | AU676314B2 (en) |
| CA (1) | CA2162877C (en) |
| WO (1) | WO1994027449A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9601398D0 (en) * | 1996-01-24 | 1996-03-27 | Piper Edwina M | Composition |
| FR2748936A1 (en) * | 1996-05-23 | 1997-11-28 | Clergeaud Jean | Composition to lessen alcohol passing into the bloodstream |
| FR2748904A1 (en) * | 1996-05-27 | 1997-11-28 | Turpin Veronique | Personalised nutritional complement containing Schuessler salts |
| AU5228098A (en) * | 1997-11-21 | 1999-06-15 | Jacqueline Turpin | Nutritional additive based on schuelssler biochemical salts |
| KR100309715B1 (en) * | 1998-04-07 | 2001-12-28 | 이명희 | Composition having function for preventing toxicity and hangover of alcohol by activation of citric acid cycle |
| KR100828708B1 (en) * | 2007-06-19 | 2008-05-09 | 씨제이제일제당 (주) | Composition for preventing or treating katzenjammer |
| KR101498780B1 (en) * | 2013-04-18 | 2015-03-04 | 씨제이제일제당 (주) | Composition for preventing or treating hangover |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0087068A1 (en) * | 1982-02-12 | 1983-08-31 | Thomas Moses Dr. Beck | Nutritional supplement |
| US4710387A (en) * | 1984-11-09 | 1987-12-01 | Melkunte Holland B.V. | Nutritional supplement preparation intended for pregnant and breast-feeding women based on milk constituents as well as a process for preparing it |
| US5108767A (en) * | 1991-06-10 | 1992-04-28 | Abbott Laboratories | Liquid nutritional product for persons receiving renal dialysis |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH370631A (en) * | 1957-05-03 | 1963-07-15 | Heinrich Dr Vogler | Process for the manufacture of a preparation intended as an additive to food and beverages |
| US5132113A (en) * | 1990-10-26 | 1992-07-21 | Maurizio Luca | Nutritional composition containing essential amino acids |
-
1994
- 1994-05-10 WO PCT/NZ1994/000042 patent/WO1994027449A1/en not_active Application Discontinuation
- 1994-05-10 AU AU65844/94A patent/AU676314B2/en not_active Ceased
- 1994-05-10 CA CA002162877A patent/CA2162877C/en not_active Expired - Fee Related
- 1994-05-10 CN CN94192255A patent/CN1124444A/en active Pending
- 1994-05-10 EP EP94913846A patent/EP0700255A4/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0087068A1 (en) * | 1982-02-12 | 1983-08-31 | Thomas Moses Dr. Beck | Nutritional supplement |
| US4710387A (en) * | 1984-11-09 | 1987-12-01 | Melkunte Holland B.V. | Nutritional supplement preparation intended for pregnant and breast-feeding women based on milk constituents as well as a process for preparing it |
| US5108767A (en) * | 1991-06-10 | 1992-04-28 | Abbott Laboratories | Liquid nutritional product for persons receiving renal dialysis |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0700255A1 (en) | 1996-03-13 |
| EP0700255A4 (en) | 1997-02-26 |
| CA2162877C (en) | 2004-04-13 |
| CA2162877A1 (en) | 1994-12-08 |
| CN1124444A (en) | 1996-06-12 |
| AU6584494A (en) | 1994-12-20 |
| WO1994027449A1 (en) | 1994-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5597585A (en) | Vitamin/mineral composition | |
| AU561734B2 (en) | Composition and method for treating alcohol and drug addicts | |
| US5215750A (en) | L-glutamine and vitamin-containing compositions effective for inducing weight loss and for weight control | |
| EP0669083B1 (en) | Creatine beverage and producing process thereof | |
| RU2000104121A (en) | THERAPEUTIC AND DIETIC COMPOSITIONS CONTAINING NECESSARY FATTY ACIDS AND BIOLOGICALLY ACTIVE DISULPHIDES | |
| AU4185696A (en) | Increasing creatine and glycogen concentration in muscle | |
| AU676314B2 (en) | Monohydrate dextrose or glucose composition | |
| EP0007691A1 (en) | Compositions for use in decreasing appetite for calories as carbohydrates | |
| EP0342955A3 (en) | Use of phytic acid or a salt thereof for treating or preventing diabetic diseases | |
| CA1282335C (en) | Method for treating the effects of alcohol | |
| Stricker et al. | Salt-seeking behavior in rats following acute sodium deficiency. | |
| KR100613618B1 (en) | Method for maintaining oxidative metabolism attendant upon exercise and food for sport | |
| KR0163583B1 (en) | Treatment of hypertension by oral administration of potassium bicarbonate | |
| KR880009654A (en) | Compositions and Methods for Reducing Toxicity of Acetaldehyde | |
| JPS57126420A (en) | Drug for digestive organ | |
| EP1238669A2 (en) | Neutrophil function inhibitors which contain glucosamine | |
| JP2002332236A (en) | Mineral-containing composition | |
| NZ265404A (en) | Composition for treatment of hangover | |
| US4499078A (en) | Methods for counteracting the deleterious effects of sodium chloride | |
| AU2010224615B2 (en) | Dietary supplement | |
| JPS58165774A (en) | Drink composition | |
| US20200215149A1 (en) | N-Phenylacetyl-L-prolylglycine ethyl ester compositions and methods for using the same | |
| JP3241173B2 (en) | Bath additive | |
| AU7767591A (en) | Pharmaceutical composition | |
| JP2002080376A (en) | Biologically active agent and medicine |